8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
May 4, 2026·SEC
Aura Biosciences, Inc.(AURA)Earnings, Financials & Key Ratios
AURA•NASDAQ
Price updated Jun 11, 2026
AboutAura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$112M-17.7%
- Net Income-$106M-22.2%
- EPS (Diluted)-1.76-0.6%
- ROE-73.52%-59.8%
- ROIC-72.36%-72.3%
- Debt/Equity0.13+2.8%
AURA Key Insights
Aura Biosciences, Inc. (AURA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 36.7% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 21.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AURA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AURA Price & Volume
Aura Biosciences, Inc. (AURA) stock price & volume — 10-year historical chart
Loading chart...
AURA Growth Metrics
Aura Biosciences, Inc. (AURA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-18.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM6.84%
Return on Capital
10 Years-56.44%
5 Years-45.76%
3 Years-51.64%
Last Year-70.8%
AURA Recent Earnings
Aura Biosciences, Inc. (AURA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 11, 2026EPS
$0.50
Est $0.40
-25.0%
Revenue
—
Q2 2026
Mar 30, 2026EPS
$0.37
Est $0.43
+14.0%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$0.40
Est $0.46
+13.0%
Revenue
—
Q3 2025
Aug 13, 2025EPS
$0.47
Est $0.49
+4.1%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.50vs $0.40-25.0% | — |
| Q2 2026 | Mar 30, 2026 | $0.37vs $0.43+14.0% | — |
| Q4 2025 | Nov 13, 2025 | $0.40vs $0.46+13.0% | — |
| Q3 2025 | Aug 13, 2025 | $0.47vs $0.49+4.1% | — |
Based on last 12 quarters of dataView full earnings history →
AURA Peer Comparison
Aura Biosciences, Inc. (AURA) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 OCUL | 1.9B | 8.70 | -6.13 | -18.67% | -5.58% | -64.55% | 0.12 | |
 RCKT | 290.45M | 2.66 | -1.32 | -70.79% | 0.09 | |||
 ADVM | 96.26M | 4.36 | -0.66 | -72.22% | -189.84% | 1.30 | ||
 REPL | 711.78M | 8.62 | -2.81 | -102.69% | 0.18 | |||
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 NUVL | 9.08B | 123.45 | -21.10 | -42.78% | ||||
 SGHT | 260.62M | 4.79 | -6.47 | -3.13% | -46.83% | -59.1% | 0.64 | |
 LNTH | 6.79B | 104.32 | 30.59 | 0.5% | 18.05% | 24.33% | 0.00 |
Compare AURA vs Peers
Aura Biosciences, Inc. (AURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AURA Income Statement
Aura Biosciences, Inc. (AURA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 509K | 0 | 0 | 0 | 1.29M | 0 | 0 | 574K |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | -509K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -1.29M▲ 0% | 0▲ 100.0% | 0▲ 0% | -574K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | 100% | - | - | - | 100% | - | - |
Operating Expenses | 23.63M | 22.21M | 35.25M | 60.3M | 83.7M | 96.12M | 112.79M | 118.05M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 4.52M | 4.16M | 10.09M | 18.06M | 19.76M | 22.81M | 22.49M | 23.7M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 19.11M | 18.04M | 25.16M | 42.24M | 63.94M | 73.3M | 90.3M | 94.92M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -574K |
Operating Income | -24.14M▲ 0% | -22.21M▲ 8.0% | -35.25M▼ 58.7% | -60.3M▼ 71.0% | -84.99M▼ 41.0% | -96.12M▼ 13.1% | -112.79M▼ 17.3% | -118.62M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | 8.01% | -58.74% | -71.05% | -40.96% | -13.09% | -17.35% | - |
EBITDA | -23.63M | -21.38M | -34.42M | -59.12M | -83.7M | -94.89M | -111.66M | -117.5M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | 9.55% | -61.02% | -71.76% | -41.57% | -13.38% | -17.67% | -15.61% |
D&A (Non-Cash Add-back) | 509K | 831K | 831K | 1.18M | 1.29M | 1.22M | 1.13M | 1.13M |
EBIT | -24.2M | -22.21M | -35.25M | -60.3M | -84.99M | -96.12M | -112.79M | -116.98M |
Net Interest Income | -5K | -3K | 0 | 1.86M | 8.59M | 9.43M | 6.63M | 6.23M |
Interest Income | 5 | 3 | 13K | 1.86M | 8.59M | 9.43M | 6.63M | 6.23M |
Interest Expense | 5K | 3K | 13K | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -60K | 0 | -1K | 1.53M | 8.72M | 9.31M | 6.71M | 6.33M |
Pretax Income | -24.2M▲ 0% | -22.21M▲ 8.2% | -35.25M▼ 58.7% | -58.76M▼ 66.7% | -76.27M▼ 29.8% | -86.81M▼ 13.8% | -106.08M▼ 22.2% | -112.29M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 137K | 112K | 108K | 100K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | -0.18% | -0.13% | -0.1% | -0.09% |
Net Income | -24.2M▲ 0% | -22.21M▲ 8.2% | -35.25M▼ 58.7% | -58.76M▼ 66.7% | -76.41M▼ 30.0% | -86.92M▼ 13.8% | -106.19M▼ 22.2% | -112.39M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | 8.24% | -58.75% | -66.7% | -30.03% | -13.76% | -22.17% | -18.69% |
Net Income (Continuing) | -24.2M | -22.21M | -35.25M | -58.76M | -76.41M | -86.92M | -106.19M | -112.39M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.01▲ 0% | -1.03▼ 12309.6% | -1.58▼ 53.4% | -1.96▼ 24.1% | -1.93▲ 1.5% | -1.75▲ 9.3% | -1.76▼ 0.6% | -1.67▲ 0% |
EPS Growth % | - | - | -53.4% | -24.05% | 1.53% | 9.33% | -0.57% | 6.84% |
EPS (Basic) | -0.01 | -1.03 | -1.58 | -1.96 | -1.93 | -1.75 | -1.76 | - |
Diluted Shares Outstanding | 2.92B | 29.22M | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M | 67.45M |
Basic Shares Outstanding | 2.92B | 29.22M | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M | 67.45M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
AURA Balance Sheet
Aura Biosciences, Inc. (AURA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 33.35M | 18.45M | 153.7M | 196.7M | 231.79M | 160.62M | 149.74M | 118.5M |
Cash & Short-Term Investments | 32.47M | 17.39M | 149.06M | 188.81M | 226.15M | 151.09M | 144.24M | 114.73M |
Cash Only | 32.47M | 17.39M | 149.06M | 121.58M | 41.06M | 31.69M | 59.52M | 84.79M |
Short-Term Investments | 0 | 0 | 0 | 67.23M | 185.09M | 119.4M | 84.73M | 29.94M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 56K | 35K | 89K | 5.72M | 3.83M | 1.83M | 5.5M | 3.77M |
Total Non-Current Assets | 3.71M | 3.65M | 6.33M | 27.23M | 23.28M | 21.88M | 19.69M | 19.17M |
Property, Plant & Equipment | 3.63M | 3.57M | 6.2M | 26.04M | 22M | 20.59M | 18.45M | 17.89M |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 75K | 0 | 0 | 768K | 0 | 0 | 0 | 768K |
Other Non-Current Assets | 0 | 75K | 125K | 423K | 1.28M | 1.29M | 1.24M | 1.28M |
Total Assets | 37.05M▲ 0% | 22.1M▼ 40.3% | 160.03M▲ 624.0% | 223.94M▲ 39.9% | 255.07M▲ 13.9% | 182.5M▼ 28.5% | 169.43M▼ 7.2% | 137.68M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | -40.35% | 623.99% | 39.93% | 13.91% | -28.45% | -7.16% | -32.39% |
Total Current Liabilities | 6.15M | 2.66M | 7.36M | 10.46M | 12.36M | 14.91M | 18.38M | 16.71M |
Accounts Payable | 2.33M | 611K | 2.4M | 2.92M | 1.79M | 2.3M | 1.55M | 2.57M |
Days Payables Outstanding | 1.67K | - | - | - | 503.67 | - | - | 1.16K |
Short-Term Debt | 0 | 15K | 0 | 0 | 0 | 0 | 3.24M | 3.27M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.52M | 1.28M | 2.65M | 3.03M | 935K | 618K | 13.59M | 10.87M |
Current Ratio | 5.42x | 6.94x | 20.90x | 18.81x | 18.76x | 10.77x | 8.15x | 7.09x |
Quick Ratio | 5.42x | 6.94x | 20.90x | 18.81x | 18.76x | 10.77x | 8.15x | 7.09x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 144K | 80K | 360K | 17.89M | 16.87M | 15.62M | 14.13M | 13.72M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 14.13M | 13.72M |
Capital Lease Obligations | 49K | 0 | 360K | 17.89M | 16.87M | 15.62M | 0 | 29.45M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 95K | 80K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6.29M | 2.74M | 7.71M | 28.35M | 29.23M | 30.53M | 32.52M | 30.43M |
Total Debt | 49K | 15K | 975K | 20.86M | 19.56M | 18.77M | 17.38M | 16.99M |
Net Debt | -32.42M | -17.38M | -148.09M | -100.72M | -21.51M | -12.92M | -42.14M | -67.8M |
Debt / Equity | 0.00x | 0.00x | 0.01x | 0.11x | 0.09x | 0.12x | 0.13x | 0.16x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.14x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.58x |
Interest Coverage | -4839.00x | -7402.00x | -2711.54x | - | - | - | - | - |
Total Equity | 30.76M▲ 0% | 19.36M▼ 37.1% | 152.31M▲ 686.6% | 195.58M▲ 28.4% | 225.85M▲ 15.5% | 151.97M▼ 32.7% | 136.91M▼ 9.9% | 107.25M▲ 0% |
Equity Growth % | - | -37.06% | 686.63% | 28.41% | 15.47% | -32.71% | -9.91% | -45.19% |
Book Value per Share | 0.01 | 0.66 | 5.21 | 6.53 | 5.70 | 3.06 | 2.27 | 1.59 |
Total Shareholders' Equity | 30.76M | 19.36M | 152.31M | 195.58M | 225.85M | 151.97M | 136.91M | 107.25M |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -94.68M | -116.89M | -152.14M | -210.9M | -287.31M | -374.23M | -480.42M | -514.1M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | -72K | 539K | 263K | -102K | -207K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AURA Cash Flow Statement
Aura Biosciences, Inc. (AURA) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -20.67M | -24.32M | -32.41M | -54.6M | -63.85M | -79.81M | -84.74M | -91.28M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -17.69% | -33.26% | -68.47% | -16.93% | -24.99% | -6.19% | -74.15% |
Net Income | -24.2M | -22.21M | -35.25M | -58.76M | -76.41M | -86.92M | -106.19M | -112.39M |
Depreciation & Amortization | 509K | 831K | 831K | 1.18M | 1.29M | 1.22M | 1.13M | 1.11M |
Stock-Based Compensation | 507K | 736K | 2.31M | 6.41M | 8.77M | 11.72M | 14.32M | 10.8M |
Deferred Taxes | 0 | 0 | 14K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 54K | -3K | 4K | -325K | -1.95M | -3.19M | 32K | 4.08M |
Working Capital Changes | 2.46M | -3.68M | -315K | -3.1M | 4.44M | -2.64M | 5.97M | 5.12M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.04M | -1.72M | 1.05M | 340K | -1.04M | 482K | -846K | 476K |
Cash from Investing | -2.22M | -771K | -2.13M | -67.87M | -113.96M | 68.82M | 35.59M | 60.68M |
Capital Expenditures | -2.22M | -771K | -2.13M | -1.09M | -709K | -1.25M | -447K | -362K |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 66.78K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -66.78K | 0 | 0 | 0 | 0 |
Cash from Financing | 39.73M | 10.04M | 166.26M | 95.63M | 97.29M | 1.59M | 77.16M | 77.36M |
Debt Issued (Net) | -37K | -34K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 39.71M | 9.91M | 165.93M | 95.2M | 95.79M | 1.59M | 77.16M | 76.28M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 57K | 163K | 334K | 430K | 1.5M | 0 | 0 | 1.08M |
Net Change in Cash | 16.84M▲ 0% | -15.06M▼ 189.4% | 131.72M▲ 974.9% | -26.84M▼ 120.4% | -80.52M▼ 200.0% | -9.39M▲ 88.3% | 27.82M▲ 396.3% | 46.57M▲ 0% |
Free Cash Flow | -22.89M▲ 0% | -25.09M▼ 9.6% | -34.53M▼ 37.6% | -55.7M▼ 61.3% | -64.56M▼ 15.9% | -81.06M▼ 25.6% | -85.19M▼ 5.1% | -91.64M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | -9.63% | -37.63% | -61.27% | -15.91% | -25.56% | -5.1% | -14.47% |
FCF per Share | -0.01 | -0.86 | -1.18 | -1.86 | -1.63 | -1.63 | -1.41 | -1.36 |
FCF Conversion (FCF/Net Income) | 0.85x | 1.10x | 0.92x | 0.93x | 0.84x | 0.92x | 0.80x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AURA Key Ratios
Aura Biosciences, Inc. (AURA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -88.6% | -41.07% | -33.78% | -36.26% | -46.01% | -73.52% | -78.12% |
| Return on Invested Capital (ROIC) | -10124.32% | -851.18% | -91.28% | -42.61% | -41.99% | -72.36% | -102.71% |
| Debt / Equity | 0.00x | 0.01x | 0.11x | 0.09x | 0.12x | 0.13x | 0.16x |
| Interest Coverage | -7402.00x | -2711.54x | - | - | - | - | - |
| FCF Conversion | 1.10x | 0.92x | 0.93x | 0.84x | 0.92x | 0.80x | 0.82x |
Related:AURA Dividend History·AURA Revenue History·AURA Price History·AURA P/E History·AURA Financial Ratios·AURA Institutional Holders
AURA SEC Filings & Documents
Aura Biosciences, Inc. (AURA) SEC filings — annual & quarterly reports (10-K, 10-Q)
AURA Frequently Asked Questions
Aura Biosciences, Inc. (AURA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aura Biosciences, Inc. (AURA) grew revenue by 0.0% over the past year. Growth has been modest.
Aura Biosciences, Inc. (AURA) reported a net loss of $112.4M for fiscal year 2025.
Dividend & Returns
Aura Biosciences, Inc. (AURA) has a return on equity (ROE) of -73.5%. Negative ROE indicates the company is unprofitable.
Aura Biosciences, Inc. (AURA) had negative free cash flow of $91.6M in fiscal year 2025, likely due to heavy capital investments.